Your browser doesn't support javascript.
loading
Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.
Eissa, Maryam A L; Lerner, Lane; Abdelfatah, Eihab; Shankar, Nakul; Canner, Joseph K; Hasan, Nesrin M; Yaghoobi, Vesal; Huang, Barry; Kerner, Zachary; Takaesu, Felipe; Wolfgang, Christopher; Kwak, Ruby; Ruiz, Michael; Tam, Matthew; Pisanic, Thomas R; Iacobuzio-Donahue, Christine A; Hruban, Ralph H; He, Jin; Wang, Tza-Huei; Wood, Laura D; Sharma, Anup; Ahuja, Nita.
Afiliação
  • Eissa MAL; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Lerner L; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Abdelfatah E; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Shankar N; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Canner JK; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Hasan NM; Department of Surgery, Yale-New Haven Health, Yale University, School of Medicine, P.O. Box 208062, New Haven, CT, 06520-8062, USA.
  • Yaghoobi V; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Huang B; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Kerner Z; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Takaesu F; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wolfgang C; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Kwak R; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ruiz M; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Tam M; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Pisanic TR; Johns Hopkins Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, MD, USA.
  • Iacobuzio-Donahue CA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Hruban RH; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • He J; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wang TH; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wood LD; The Sol Goldman Pancreatic Cancer Research Center, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Sharma A; Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ahuja N; Johns Hopkins Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, MD, USA.
Clin Epigenetics ; 11(1): 59, 2019 04 05.
Article em En | MEDLINE | ID: mdl-30953539
BACKGROUND: Despite improvements in cancer management, most pancreatic cancers are still diagnosed at an advanced stage. We have recently identified promoter DNA methylation of the genes ADAMTS1 and BNC1 as potential blood biomarkers of pancreas cancer. In this study, we validate this biomarker panel in peripheral cell-free tumor DNA of patients with pancreatic cancer. RESULTS: Sensitivity and specificity for each gene are as follows: ADAMTS1 87.2% and 95.8% (AUC = 0.91; 95% CI 0.71-0.86) and BNC1 64.1% and 93.7% (AUC = 0.79; 95% CI 0.63-0.78). When using methylation of either gene as a combination panel, sensitivity increases to 97.3% and specificity to 91.6% (AUC = 0.95; 95% CI 0.77-0.90). Adding pre-operative CA 19-9 values to the combined two-gene methylation panel did not improve sensitivity. Methylation of ADAMTS1 was found to be positive in 87.5% (7/8) of stage I, 77.8% (7/9) of stage IIA, and 90% (18/20) of stage IIB disease. Similarly, BNC1 was positive in 62.5% (5/8) of stage I patients, 55.6% (5/9) of stage IIA, and 65% (13/20) of patients with stage IIB disease. The two-gene panel (ADAMTS1 and/or BNC1) was positive in 100% (8/8) of stage I, 88.9% (8/9) of stage IIA, and 100% (20/20) of stage IIB disease. The sensitivity and specificity of the two-gene panel for localized pancreatic cancer (stages I and II), where the cancer is eligible for surgical resection with curative potential, was 94.8% and 91.6% respectively. Additionally, the two-gene panel exhibited an AUC of 0.95 (95% CI 0.90-0.98) compared to 57.1% for CA 19-9 alone. CONCLUSION: The methylation status of ADAMTS1 and BNC1 in cfDNA shows promise for detecting pancreatic cancer during the early stages when curative resection of the tumor is still possible. This minimally invasive blood-based biomarker panel could be used as a promising tool for diagnosis and screening in a select subset of high-risk populations.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Fatores de Transcrição / Metilação de DNA / Proteínas de Ligação a DNA / Proteína ADAMTS1 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Female / Humans / Male Idioma: En Revista: Clin Epigenetics Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Fatores de Transcrição / Metilação de DNA / Proteínas de Ligação a DNA / Proteína ADAMTS1 Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Female / Humans / Male Idioma: En Revista: Clin Epigenetics Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos